169939-93-9

LY333531 is an inhibitor of PKCβ (IC₅₀s = 4.7 and 5.9 nM for PKCβ1 and PKCβ2, respectively). It is selective for PKCβ1 and PKCβ2 over PKCα, -γ, -δ, -ε, -ζ, and -η (IC₅₀s = 360, 300, 250, >100,000, and 52 nM, respectively). LY333531 also inhibits glycogen synthase kinase 3β (GSK3β; IC₅₀ = 39.4 nM). It inhibits neutrophil extracellular trap (NET) formation induced by phorbol 12-myristate 13-acetate (PMA; ) in primary human neutrophils when used at a concentration of 1 μM. LY333531 increases the mechanical nociceptive threshold in a rat model of diabetic hyperalgesia induced by streptozotocin (STZ; ).

A protein kinase C (PKC) β inhibitor, exhibits significant anti-angiogenic activity that reduces the response of vascular endothelial cells to stimulation by vascular endothelial growth factor (VEGF). It is used in treatment of diabetic microvascular comp

Ruboxistaurin is a protein kinase C (PKC) β inhibitor, exhibits significant anti-angiogenic activity that reduces the response of vascular endothelial cells to stimulation by vascular endothelial grow th factor (VEGF). Ruboxistaurin is used in treatment of diabetic microvascular complications.

PKCβI: 4.7 nM (IC₅₀); PKCβII: 5.9 nM (IC₅₀); PKCη: 52 nM (IC₅₀); PKCδ: 250 nM (IC₅₀); PKCγ: 300 nM (IC₅₀); PKCα: 360 nM (IC₅₀); PKCε: 600 nM (IC₅₀)

[1] MICHAEL R. JIROUSEK. (S)-13-[(Dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16,21-dimetheno- 1H,13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and Related Analogues: Isozyme Selective Inhibitors of Protein Kinase Cβ[J]. Journal of Medicinal Chemistry, 1996, 39 14: 2664-2671. DOI: 10.1021/jm950588y
[2] PATRICIA A. VIGNAUX. Machine Learning for Discovery of GSK3β Inhibitors[J]. ACS Omega, 2020, 5 41: 26551-26561. DOI: 10.1021/acsomega.0c03302
[3] ROBERT D GRAY. Activation of conventional protein kinase C (PKC) is critical in the generation of human neutrophil extracellular traps.[J]. Journal of Inflammation-London, 2013, 10 1: 12. DOI: 10.1186/1476-9255-10-12
[4] HYOH KIM. Protein kinase Cbeta selective inhibitor LY333531 attenuates diabetic hyperalgesia through ameliorating cGMP level of dorsal root ganglion neurons.[J]. Diabetes, 2003, 52 8: 2102-2109. DOI: 10.2337/diabetes.52.8.2102